Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
225 stopped studies mapped to Neuroendocrine Carcinoma and descendants · 90% state a reason
Over the 225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung… | Phase 1 / Phase 2 | terminated | Dec 24, 2019 | Ascentage Pharma Group Inc. | Sponsor decision | Sponsor / business decision |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by the IRB 5/26/22 due to non-compliance | Other (stated, no rule matched) |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2021 | Elpiscience Biopharma, Ltd. | Sponsor's clinical development strategy adjustment | Sponsor / business decision |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer… | Phase 3 | terminated | Feb 3, 2006 | Sumitomo Pharma Co., Ltd. | not stated | Not stated |
| NCT02584829 | Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without… | Phase 1 / Phase 2 | terminated | Oct 23, 2015 | Fred Hutchinson Cancer Center | Terminated due to loss in funding | Funding |
| NCT04525391 | AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer(SUKSES-N5) | Phase 2 | terminated | Aug 25, 2020 | Se-Hoon Lee | Recommended completion of the study due to SUSAR occurring in other clinical trials conducted with… | Other (stated, no rule matched) |
| NCT04874831 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic… | Phase 2 | withdrawn | May 6, 2021 | 4SC AG | Refocusing of sponsor's clinical development program. No safety concern or change of the… | Safety / toxicity |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung… | Phase 2 | terminated | Oct 17, 2016 | NYU Langone Health | This study was terminated as the standard of care for small cell lung cancer changed in 2018 to… | Other (stated, no rule matched) |
| NCT04422210 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax… | Phase 1 | terminated | Jun 9, 2020 | Hoffmann-La Roche | Decision to discontinue the study based on broader development and strategic prioritisation. The… | Sponsor / business decision |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase 2 | withdrawn | Feb 12, 2019 | Antonio Fojo | Closed by sponsor | Other (stated, no rule matched) |
| NCT04677361 | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With… | Early Phase 1 | withdrawn | Dec 21, 2020 | Fox Chase Cancer Center | Grantor shifted focus in disease, funding was stopped | Funding |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | Phase 1 | terminated | Jan 2, 2018 | Ascentage Pharma Group Inc. | The company adjusts strategy. | Sponsor / business decision |
| NCT03988647 | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jun 17, 2019 | Stanford University | Business decision | Sponsor / business decision |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line…(MERU) | Phase 3 | terminated | Jan 26, 2017 | AbbVie | Independent Data Monitoring Committee recommendation | Other (stated, no rule matched) |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT01573338 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together… | Phase 1 / Phase 2 | terminated | Apr 9, 2012 | Bayer | not stated | Not stated |
| NCT02722369 | STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus… | Phase 2 | terminated | Mar 30, 2016 | University College, London | Low recruitment, lack of efficacy and increased adverse events in investigational arm. | Safety / toxicity |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | Phase 1 / Phase 2 | withdrawn | Sep 10, 2020 | Virginia Commonwealth University | AbbVie decided to stop trial involving Venetoclax for safety measures needed | Safety / toxicity |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade… | Phase 2 | withdrawn | Apr 3, 2019 | Ochsner Health System | Lack of accrual | Enrollment / accrual |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based… | Phase 3 | terminated | May 4, 2018 | Zai Lab (Shanghai) Co., Ltd. | As the treatment model of extensive-stage small cell lung cancer changed rapidly and the enrollment… | Enrollment / accrual |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | Phase 2 | terminated | Feb 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin…(NeoFIND) | Phase 2 | terminated | Oct 30, 2018 | Advanced Accelerator Applications | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC)… | Phase 1 | terminated | Apr 17, 2017 | EMD Serono Research & Development Institute, Inc. | Enrollment in the study was prematurely terminated due to recruitment challenges and not due to… | Safety / toxicity |
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum…(PINNACLE) | Phase 1 / Phase 2 | terminated | May 22, 2013 | OncoMed Pharmaceuticals, Inc. | OMP-59R5 did not improve PFS. | Other (stated, no rule matched) |
| NCT02315625 | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced… | Phase 2 | terminated | Dec 12, 2014 | National Cancer Institute (NCI) | Study closed due to poor accrual. | Enrollment / accrual |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Sep 27, 2019 | M.D. Anderson Cancer Center | No Participants Registered | Other (stated, no rule matched) |
| NCT03607682 | Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With… | N/A | terminated | Jul 31, 2018 | Vanderbilt-Ingram Cancer Center | PI left institution and loss of funding | Investigator |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or… | Phase 1 / Phase 2 | terminated | Jan 20, 2017 | AbbVie | Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2. | Safety / toxicity |
| NCT01803269 | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating… | Phase 2 | terminated | Mar 4, 2013 | University of Chicago | Due to lack of activity and slow accrual | Enrollment / accrual |
| NCT01809756 | The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated…(CARACTER) | N/A | terminated | Mar 13, 2013 | Amphia Hospital | bad taste of Caphosol - early stop of intake by patients | Other (stated, no rule matched) |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | Phase 1 | terminated | Apr 26, 2010 | University of Maryland, Baltimore | Toxicity was not felt to be acceptable for further development. | Safety / toxicity |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients… | Phase 1 | terminated | Jun 30, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT03168594 | Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With… | Phase 2 | terminated | May 30, 2017 | Peking University | The enrollment was terminated early because the premature analysis found similar response in the… | Enrollment / accrual |
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | — | terminated | Apr 10, 2012 | Addario Lung Cancer Medical Institute | interim assessment by sponsor | Other (stated, no rule matched) |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | Phase 1 | terminated | Jul 20, 2010 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT01913691 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | Phase 2 | withdrawn | Aug 1, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or… | Phase 1 | terminated | Oct 29, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | Budget/Funding | Funding |
| NCT02034123 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | Phase 1 | terminated | Jan 13, 2014 | GlaxoSmithKline | The risk benefit in relapsed refractory SCLC does not favor continuation of the study | Other (stated, no rule matched) |
| NCT00537511 | A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047… | Phase 1 / Phase 2 | terminated | Oct 1, 2007 | Celgene | This study was terminated for administrative reasons. | Other (stated, no rule matched) |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced… | Phase 1 / Phase 2 | withdrawn | Jan 8, 2014 | University of Maryland, Baltimore | PI has left the study institution. | Other (stated, no rule matched) |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02937402 | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune… | N/A | terminated | Oct 18, 2016 | Vanderbilt-Ingram Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given… | Phase 2 | terminated | Apr 9, 2014 | Clovis Oncology, Inc. | not stated | Not stated |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With… | Phase 1 | terminated | Feb 20, 2015 | Millennium Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 4, 2015 | Zhejiang Provincial People's Hospital | No recruitment. | Enrollment / accrual |
| NCT00969306 | Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients(Chloroquine IV) | Phase 1 | terminated | Sep 1, 2009 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 15, 2022source: clinicaltrials